the general population as well. 1 Consequently, there is an increased risk of overanalysing patients and generating false-positive laboratory results. 2 As the haemostatic system is complex, disturbances can occur in either primary haemostasis, secondary haemostasis, fibrinolysis or a combination of these. Current screening and confirmatory laboratory tests lack sufficient specificity and sensitivity. Only in a limited number of patients, single gene analysis yields a clear diagnosis. Consequently, many patients remain without a definitive diagnosis. 3 Therefore, improved diagnostic approaches are needed to establish a more personalized based treatment and limit bleeding complications.
Novel strategies, such as proteomics, metabolomics and genomics, are slowly incorporated into clinical practice. [4] [5] [6] Continued next-generation sequencing (NGS) efforts have already significantly improved our understanding of the pathobiology in other diseases such as acute myeloid leukaemia and changed treatment towards more individualized therapy. 7 Routine diagnostic whole exome sequencing (WES) in our genetic department has shown to be an effective tool to elucidate the genetic defect underlying many different types of heterogeneous disorders and we hypothesize that such an approach would also benefit the diagnostics of bleeding disorders. [8] [9] [10] [11] Several research groups have introduced the use of NGS approaches in patients with a bleeding diathesis. [12] [13] [14] [15] [16] [17] Thus far, only one research group incorporated WES in their routine diagnostic workup. 13 In 2016, we implemented WES in the diagnostic pathway of patients with thrombocytopenia, platelet function abnormalities or an unexplained bleeding tendency after accomplishing the standard laboratory assays at the Radboud university medical center with the main goal to better understand the clinical phenotype. The results of the first interim analysis are presented here.
| MATERIAL S AND ME THODS

| Patient description
Patients with a suspected bleeding diathesis were analyzed using the Tosetto BAT score and standard diagnostic tests covering coagulation, platelet function and fibrinolysis. 18 These included platelet function analysis (PFA), activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, FVIII levels, von Willebrand factor (VWF) activity and antigen, collagen binding capacity, α2-antiplasmin, FXIII levels, platelet aggregation assays, plasminogen activator inhibitor type 1 (PAI-1) activity and antigen, tissue plasminogen activator (TPA) and euglobulin clot lysis time. After these conventional diagnostic assays, the patients were distributed into three separate groups either due to an increased BAT without any laboratory abnormalities or with abnormal platelet count or function without a definite diagnosis. Eighty-seven patients diagnosed with thrombocytopenia (defined as a platelet count <150 × 10 9 /L with or without a platelet function abnormalities, group A), a platelet function abnormality (defined as abnormal platelet aggregation and normal platelet count, group B), or a bleeding diathesis of unknown origin (group C) were subjected to WES between 1 January 2016 and 1 January 
| Exome sequencing
Genomic DNA was isolated from whole blood. Exonic enrichment (Agilent Technologies, Santa Clara, California, USA) and sequencing (Illumina Hiseq) generating reads to a median coverage of >75× was performed at Beijing Genome Institute Europe, Denmark.
Sequenced reads were mapped to the hg19 reference genome using the mapping algorithm from bwa (version 0.5. 
| RE SULTS
| Basic patient characteristics and WES results
Eighteen variants were found with the gene panel in 15 of 87 patients (17%). All variants that were discovered are shown in Table 2 .
Mean age at WES inclusion was 41 years, with 82% female patients.
Overall results and workflow are shown in Figure 1 .
Seventeen patients were categorized in group A. This group had the highest incidence of pathogenic causative variants with four of the 17 cases solved (24%). Two patients had a heterozygous MYH9 variant causing an autosomal dominant MYH9 associated bleeding disorder. One patient had a heterozygous SLFN14 variant causing autosomal dominant platelet secretion defects. 26 In addition, one patient had a homozygous GP9 variant causing autosomal recessive Bernard-Soulier syndrome. A VUS was identified in GFI1B corresponding to autosomal dominant grey platelet syndrome, and a carriership in FGG corresponding to autosomal recessive afibrinogenemia. 27 Group B consisted of 19 patients, in whom one causative variant was found (5%): a homozygous P2RY12 variant leading to an autosomal recessive impairment of platelet response to ADP. 28 One heterozygous VUS was found in VWF and furthermore a VUS in MASTL was classified as likely non-pathogenic (class 2) based on segregation analysis.
Fifty-one patients were categorized as group C. In this group, one patient carried a heterozygous F7 variant and a heterozygous F13A1 variant. Another patient had combined carriership of F2, F8
and VWF variants (all heterozygous). The found variants in these two patients (4%) were considered to play a major role in the explanation of the bleeding phenotypes. Five carrierships of autosomal recessive disorders were found in GP1BA (corresponding to Bernard-Soulier syndrome) MPL (corresponding to myelofibrosis, thrombocythemia or thrombocytopenia), F2, F5 and F11. Two heterozygous VUSes in one patient in NBEAL2 were not considered causative as segregation analysis showed that these variants were on the same allele (and thus not compound heterozygous), while grey platelet syndrome is an autosomal recessive disorder. 
| Genotype translation to clinical practice
The additional benefit of performing WES to the diagnostic workup is illustrated by the following five case descriptions, highlighted in blue in Table 2 and Figure 1 :
In the first case ( Table 2 , patient 11), a class 5 variant in GP1BA
was identified in a 4-year-old boy with a bleeding tendency. His paediatric bleeding score was 3, due to rebleeding after tonsillectomy for which two re-operations were necessary. Besides these surgical interventions, he had no other haemostatic challenges so far. His mother has a bleeding tendency with a BAT score of 6, and he has a sister with a paediatric bleeding score of 1 (based on easy bruising). His father is unknown. The child had low-normal VWF levels with a ristocetin cofactor activity of 33%, VWF antigen of 43%
and FVIII activity of 59% but no causative variants in the VWF gene.
His blood group was O+. The PFA showed a prolonged epinephrine (186 seconds, cut-off: <170) and ADP (162 seconds, cut-off: <120)
response. Whole blood platelet aggregometry showed normal platelet aggregation with ADP, collagen, arachidonic acid and adrenalin.
Other haemostatic screening assays (fibrinogen, FVIII, FIX, FXI, FXII, PT and APTT) were normal. Hence, the bleeding phenotype of this child might be explained by the combination of low von Willebrand disease (VWD) parameters together with the heterozygous pathogenic GP1BA variant, leading to an inadequate primary haemostasis.
Secondly, a 76-year-old woman ( tendency, whereby the individual haemostatic levels are influenced by age.
In the third case, two heterozygous class 4 variants were found in F7 and F13A in an 18-year-old woman with a bleeding tendency ( Table 2, fibrinogen) were normal, whereas PFA could not be determined because of the thrombocytopenia. In this patient, a heterozygous FGG variant was found. Although this is only a carriership with normal fibrinogen levels, this variant has been described earlier in a patient with a thrombocytopenia. 29 Finally, a 58-year-old woman was referred with a bleeding score of 8, consisting of easy bruising, prolonged bleeding from minor wounds, maenorrhagia and bleeding after caesarean section requiring blood transfusion (not incorporated in Table 2 ). 
| D ISCUSS I ON
The value of WES is demonstrated by the detection of rare causative variants that are not found by conventional laboratory diagnostics. 7, 17 The main goal of our study was to evaluate the additional value of WES to the standard diagnostic workup in patients with an increased bleeding tendency to unravel the clinical phenotype.
By introducing WES after conventional laboratory assays, 18 variants were found in 15 patients of a total of 87 patients with an un- However, a combination of low-normal Factor VII and factor XIII levels can predispose patients to inadequate thrombin generation and fibrin clot formation during events where there is an increased haemostatic demand, such as in the menstrual period or during surgery. 34, 35 In the fourth case, the found variant in FGG does not appear to be related to the thrombocytopenia at first sight.
However, this variant has been described previously in a patient with hypofibrinogenemia, and a thrombocytopenia as well. 29 This is a very interesting finding because in theory, this variant can cause an increased binding of fibrinogen to the GPIIbIIIa receptor, which can cause small platelet aggregates and subsequent thrombocytopenia due to platelet consumption. In this study, we chose to include only class 3 variants corresponding to autosomal dominant bleeding disorders as they are potentially pathogenic, whereas a class 3 variant corresponding to an autosomal recessive disorder can cause carriership at most, with unknown significance. A limitation of our study is the small number of patients that were analyzed. In addition, our study reflects the diagnostic workup retrospectively and does not have a prospective design. A prospective extension study is planned with incorporation of WES in the diagnostic workup with the addition of performing family-based segregation analysis.
We emphasize the additive benefit of implementing WES in the diagnostic workup of patients with an increased bleeding phenotype without a definite diagnosis after performing conventional laboratory assays. A pitfall of these latter assays is that they determine a limited part of the primary or secondary haemostasis and do not reflect the total haemostatic system. NGS techniques are a valuable tool to assist in evaluating the haemostasis balance as a whole. We pose that combinations of mild abnormalities in one haemostatic process (eg, the primary haemostasis) or different processes (primary, secondary haemostasis and/or fibrinolysis) can lead to an increased bleeding tendency which is not detected by current conventional laboratory assays.
However, besides implementation of NGS techniques, functional
haemostatic assays need to be improved. Currently, flow cytometry-based platelet function diagnostic tests are being developed and global haemostatic assays are implemented in clinical practice.
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| CON CLUS ION
Based on the results of this diagnostic approach presented here and recently published genetic studies in bleeding disorders, we propose to include NGS techniques in the diagnostic workup for unexplained bleeding disorders. 13 We advise to discuss the results in a multidisciplinary team including haematologists, laboratory specialists and geneticists. Discovery of combinations of (novel) genes that predispose to bleeding will increase the diagnostic yield in patients with an unexplained bleeding diathesis. To accept NGS techniques in the standard diagnostic workup of patients with bleeding tendency, prospective studies with larger patient numbers and cost-benefit analyses are needed. 
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